News
Important Only
Churchill Resources Announces Fully Subscribed $700,000 Private Placement
June 26 (Reuters) - Churchill Resources Inc CRI.V:CHURCHILL RESOURCES ANNOUNCES FULLY SUBSCRIBED $700,000 PRIVATE PLACEMENT AND STRATEGIC LEADERSHIP CHANGES TO BOLSTER GROWTH AND OPERATIONAL EXECUTIONCHURCHILL RESOURCES INC - PAUL SOBIE STEPS DOWN AS CEO, REMAINS PRESIDENTCHURCHILL RESOURCES INC - C...Reuters
Thu, Jun 26
BBC rolls out paid subscriptions for US users
LONDON, June 26 (Reuters) - The BBC is rolling out paid subscriptions in the United States, it said on Thursday, as the publicly-funded broadcaster explores new revenue streams amid negotiations with the British government over its funding.The BBC has in recent years seen a fall in the number of peo...Reuters
Thu, Jun 26
Fitch Uzbekistan Upgrade Reflects Accelerated Reform Progress & Favourable Medium-Term Growth Prospects
June 26 (Reuters) - FITCH: UZBEKISTAN UPGRADE REFLECTS ACCELERATED REFORM PROGRESS & FAVOURABLE MEDIUM-TERM GROWTH PROSPECTSFITCH: UZBEKISTAN'S RATING CONTINUES TO REFLECT LOW PUBLIC DEBT, SIZEABLE EXTERNAL & FISCAL BUFFERS AND HIGH POTENTIAL GROWTHFurther company coverage: [ ]Reuters
Thu, Jun 26
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From The U.S. Food And Drug Administration For Adx-2191
June 26 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:ALDEYRA THERAPEUTICS RECEIVES SPECIAL PROTOCOL ASSESSMENT AGREEMENT LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ADX-2191 FOR THE TREATMENT OF PRIMARY VITREORETINAL LYMPHOMAALDEYRA THERAPEUTICS INC - CLINICAL TRIAL EXPECTED TO BEGIN IN SEC...Reuters
Thu, Jun 26
Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline
June 26 (Reuters) - CRISPR Therapeutics AG CRSP.BN:CRISPR THERAPEUTICS REPORTS POSITIVE ADDITIONAL PHASE 1 DATA FOR CTX310™ TARGETING ANGPTL3 AND PROVIDES UPDATE ON IN VIVO CARDIOVASCULAR PIPELINECRISPR THERAPEUTICS AG - CTX310 SHOWS UP TO 82% TG AND 86% LDL REDUCTIONCRISPR THERAPEUTICS AG - CTX320 ...Reuters
Thu, Jun 26
Altimmune Announces Positive Topline Results From The Impact Phase 2B Trial Of Pemvidutide
June 26 (Reuters) - Altimmune Inc ALT.O:ALTIMMUNE ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN THE TREATMENT OF MASHALTIMMUNE INC - TRIAL ACHIEVES 59.1% MASH RESOLUTION WITHOUT WORSENING FIBROSISALTIMMUNE INC: TRIAL MET ITS PRIMARY ENDPOINTALTIMMUNE INC - WEIGH...Reuters
Thu, Jun 26
Walgreens tops quarterly profit estimates as Sycamore deal nears completion
June 26 (Reuters) - Walgreens Boots Alliance WBA.O, which is being taken private by Sycamore Partners, beat analysts' estimates for third-quarter profit on Thursday, as store closures and cost-cutting aided turnaround efforts at the second-largest U.S. pharmacy chain. On an adjusted basis, th...Reuters
Thu, Jun 26
Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
June 26 (Reuters) - Revive Therapeutics Ltd RVV.CD:REVIVE THERAPEUTICS NEARS COMPLETION OF KEY NERVE AGENT COUNTERMEASURE STUDY WITH CANADIAN DEPARTMENT OF NATIONAL DEFENCE HIGHLIGHTING SIGNIFICANT STOCKPILING OPPORTUNITYREVIVE THERAPEUTICS LTD - BUCILLAMINE STUDY TO CONCLUDE BY SEPTEMBER 2025REVIVE...Reuters
Thu, Jun 26
Ast Spacemobile: On June 23, Bankruptcy Court Approved Ast Spacemobile-Ligado Networks Deal
June 26 (Reuters) - AST SpaceMobile Inc ASTS.O:AST SPACEMOBILE INC - ON JUNE 23, BANKRUPTCY COURT APPROVED AST SPACEMOBILE-LIGADO NETWORKS DEAL - SEC FILINGSource text: [ID:n0001641172-25-016581]Reuters
Thu, Jun 26
Invivyd Announces Positive Full Phase 1/2 Clinical Data For Vyd2311
June 26 (Reuters) - Invivyd Inc IVVD.O:INVIVYD ANNOUNCES POSITIVE FULL PHASE 1/2 CLINICAL DATA FOR VYD2311, A NEXT GENERATION COVID-19 MONOCLONAL ANTIBODY FOR POTENTIAL USE AS A NON-VACCINE PREVENTATIVE AND FOR TREATMENT OF ACTIVE INFECTIONINVIVYD INC - VYD2311 SHOWS ATTRACTIVE SAFETY PROFILE ACROSS...Reuters
Thu, Jun 26
Kalvista Pharmaceuticals Enters Into Licensing Agreement With Pendopharm To Commercialize Sebetralstat For Hae In Canada
June 26 (Reuters) - Kalvista Pharmaceuticals Inc KALV.O:KALVISTA PHARMACEUTICALS ENTERS INTO LICENSING AGREEMENT WITH PENDOPHARM TO COMMERCIALIZE SEBETRALSTAT FOR HAE IN CANADAKALVISTA PHARMACEUTICALS INC: FINANCIAL TERMS OF AGREEMENT ARE NOT BEING DISCLOSEDReuters
Thu, Jun 26
